Table 3.
Overview of the oncological outcome.
| Author | Median F/U Period | Tumor Location (Liver Site) |
Tumor Progress and Location | Tumor Response (RECIST) | Post-RE Surgery |
|---|---|---|---|---|---|
| Edeline [21] | 2 mo | Right: 23 Left: 11 |
Ipsilateral: 3 | PR: 7 SD: 17 PD: 3 |
- |
| Fernandez-Ros [22] | - | Right: 66 Left: 17 |
- | - | Hx+LTx: 15 |
| Gaba [15] | 49 mo | Right: 20 | None | PR: 14 SD: 6 |
Hx: 1 LTx: 1 |
| Gabr [34] | 1 mo | Right: 25 Left: 6 |
Location not specified: 3 | CR: 9 #; 0 * PR: 9 #; 8 * SD: 13 #; 20 * PD: 0 #; 3 * |
Hx: 31 |
| Garlipp [23] | 3 mo | Right: 26 | Contralateral: 1 | CR: 1 PR: 5 SD: 19 PD: 1 |
- |
| Goebel [24] | - | Right: 75 | - | - | - |
| Jakobs [14] | - | Bilobar: 32 | - | - | - |
| Justinger [25] | 5.1 mo | Right: 10 Left: 1 Bilobar: 2 |
Contralateral: 1 Extrahepatic: 1 |
- | Hx: 11 |
| Lewandowski [26] | 6.3 mo | Right: 13 | None | CR: 1 #; 0 * PR: 5 #; 3 * SD: 8 #; 10 * |
Hx: 13 |
| Orcutt [27] | 6 mo | Right: 25 | None | - | - |
| Palard [28] | 12.5 mo | - | Ipsilateral: 8 Contralateral: 14 |
- | Hx: 9 |
| Rayar [29] | 16 mo | Right: 3 Bilobar: 5 |
None | - | Hx: 8 |
| Teo [30] | 6 mo | Right: 17 | Contralateral: 4 | CR: 2 PR: 5 SD: 6 PD: 4 |
Hx: 1 |
| Teo [31] | 12 mo | Right: 22Left: 2 | Contralateral: 5 | PR: 2 SD: 17 PD: 5 |
Hx: 8 |
| Theysohn [32] | - | Right: 45 | - | - | - |
| Vouche [33] | 9 mo | Right: 83 | Contralateral: 17 | Missing: 79 PD: 4 |
Hx: 5 LTx: 6 |
| Total | 11 mo | Right: 453 Left: 37 Bilobar: 39 |
Ipsilateral: 11/360 (3%) Contralateral: 42/360 (12%) Extrahepatic: 1/360 (1%) Not specified: 3/360 (1%) |
CR: 3/118 (3%) PR: 33/118 (28%) SD: 65/118 (55%) PD: 17/118 (14%) |
109/362 (30%) |
F/U: follow-up, RE: radioembolization, RECIST: response evaluation criteria in solid tumors, mo: months, Hx: hepatectomy, LTx: liver transplantation, CR: complete response, PR: partial response, SD: stable disease, PD: progressive disease, -: data not available, * according to World Health Organization (WHO) criteria, # according to European Association for the Study of the Liver (EASL) response criteria.